CD30: Expression and function in health and disease

Seminars in Immunology

Volumn 10, Issue 6, 1998, Pages 457-470

  Horie, Ryouichi ^b   Watanabe, Toshiki ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

ALCL; CD30 ligand; Hodgkin's disease; TNFR superfamily; TRAF protein

Indexed keywords

CD30 ANTIGEN; COMPLEMENTARY DNA; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ANTIGEN EXPRESSION; B LYMPHOCYTE; EPITHELIUM CELL; GRANULOCYTE; HELPER CELL; HODGKIN DISEASE; HUMAN; LEUKEMIA CELL; LYMPHATIC LEUKEMIA; LYMPHOCYTE SUBPOPULATION; MOLECULAR CLONING; NONHUMAN; PROTEIN STRUCTURE; REED STERNBERG CELL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; VIRUS INFECTION;

EID: 0032387839     PISSN: 10445323     EISSN: None     Source Type: Journal    
DOI: 10.1006/smim.1998.0156     Document Type: Article

References (124)

1. 1. Schwab U, Stein H, Gerdes J, Lemke H, Kirchner H, Schaadt M, Diehl V (1982) Production of a monoclonal antibody specific for Hodgkin and Sternberg Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature 299:65-67
2. 2. Stein H, Mason DY, Gerdes J, O'Conner N, Wainscoat J, Pallsen G, Gatter K, Falini B, Delsol G, Lemke H, Schwarting R, Lennert K(1985) The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue. Evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66:848-858
3. 3. Schwarting R, Gerdes J, Dürkop H, Falini B, Pilieri S, Stein H(1989) Ber-H2: A new anti Ki-1 (CD30) monoclonal antibody directed at a formol resistant epitope. Blood 74:1678-1684
4. 4. Andreesen R, Osterholz J, Lohr GW, Bross KJ (1984) A Hodgkin's cell-specific antigen is expressed on a subset of auto-and alloactivated T (helper) lymphoblasts. Blood 63:1299-1302
5. 5. Ellis TM, Simms PE, Slivnick DJ, Jäck H-M, Fisher RI (1993) CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO + T cells. J Immunol 151:2380-2389
6. 6. Josimovic-Alasevic O, Dürkop H, Schwarting R, Backe E, Stein H, Diamantstein T (1989) Ki-1 (CD30) antigen is released by Ki-1 positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay. Eur J Immunol 19:157-162
7. 7. Pizzolo G, Stein H, Josimovic-Alasevic O, Vinante F, Zanotti R, Chilosi M, Feller AC, Diamantstein T (1990) Increased serum levels of soluble IL-2 receptor, CD30 and CD8 molecules, and gamma-interferon in angioimmunoblastic lymphadenopathy. Possible pathogenic role of immunoactivation mechanisms. Br J Haematol 75:485-488
8. 8. Pizzolo G, Vinante F, Chilosi M, Dallenbach F, Josimovic-Alasevic O, Diamantstein T, Stein H (1990) Serum levels of soluble CD30 molecule (Ki-1 antigen) in Hodgkin's disease: relationship with disease activity and clinical stage. Br J Haematol 75:282-284
9. 9. Nadali G, Vinante F, Stein H, Todeschini G, Tecchio C, Morosato L, Chilosi M, Menestrina F, Kinney MC, Greer JP, Latza U, Perona G, Pizzolo G (1995) Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30 + anaplastic large-cell lymphoma. J Clin Oncol 13:1355-1360
10. 10. Caligaris-Cappio F, Bertero MT, Converso M, Stacchini A, Vinante F, Romagnani S, Pizzolo G (1995) Circulating levels of soluble CD30, a marker of cells producing Th2-type cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity. Clin Exp Rheumatol 13:339-343
11. 11. Dürkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H (1992) Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 68:421-427
12. 12. Smith CA, Grüss HJ, Davis T, Anderson D, Farrah T, Baker E, Southerland GR, Branann CI, Copeland NG, Jenkins NA, Grabstein KH, Gliniak B, McAlister IB, Fanslow W, Alderson M, Falk B, Gimpel S, Gillis S, Din WS, Goodwin RG, Armitage RJ (1993) CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 73:1349-1360
13. 13. Grüss HJ, Boiani N, Williams DE, Armitage RJ, Smith CA, Goodwin RG (1994) Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood 83:2045-2056
14. 14. Smith CA, Farrah T, Goodwin RG (1994) The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 76:959-962
15. 15. Baker SJ, Reddy P (1996) Transducers of life and death: TNF receptor superfamily and associated proteins. Oncogene 12:1-9
16. 16. Bazzoni F, Beutler B (1996) The tumor necrosis factor ligand and receptor families. N Engl J Med 334:1717-1725
17. 17. Biswas P, Smith CA, Goletti D, Hardy EC, Jackson RW, Fauci AS (1995) Cross-linking of CD30 induces HIV expression in chronically infected T cells. Immunity 2:587-596
18. 18. McDonald PP, Cassatella MA, Bald A, Maggi E, Romagnani S, Gruss HJ, Pizzolo G (1995) CD30 ligation induces nuclear factor-kappa B activation in human T cell lines. Eur J Immunol 25:2870-2876
19. 19. Gedrich RW, Gilfillan MC, Ducket CS, Van Dongen JL, Thompson CB (1996) CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteins. J Biol Chem 271:12852-12858
20. 20. Lee SY, Lee SY, Kandala G, Liou M-L, Choi Y (1996) CD30/TNF receptor-associated factor interaction: NF-kappa B activation and binding specificity. Proc Natl Acad Sci 93:9699-9703
21. 21. Aizawa S, Nakano H, Ishida T, Horie R, Nagai M, Ito K, Yagita H, Okumura K, Inoue J, Watanabe T (1997) Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NF-κ B activation. J Biol Chem 272:2042-2045
22. 22. Boucher L-M, Marengere LEM, Lu Y, Thurkral S, Mak TM (1997) Binding sites of cytoplasmic effectors TRAF1, 2, and 3 on CD30 and other members of the TNF receptor superfamily. Biochem Biophys Comm 233:592-600
23. 23. Duckett CS, Gedrich RW, Gilfillan MC, Thompson CB (1997) Induction of nuclear factor kB by the CD30 receptor is mediated by TRAF1 and TRAF2. Mol Cell Biol 17:1535-1542
24. 24. Tsitsikov E, Wright DA, Geha RS (1997) CD30 induction of human immunodeficiency virus gene transcription is mediated by TRAF2. Proc Natl Acad Sci 94:1390-1395
25. 25. Nawrocki JF, Kirstein ES, Fisher RI (1988) Biochemical and structural properties of a Hodgkin's disease-related membrane protein. J Immunol 141:672-680
26. 26. Bowen MA, Lee RK, Miragliotta G, Nam SY, Podack ER (1996) Structure and expression of murine CD30 and its role in cytokine production. J Immunol 156:442-449
27. 27. Aizawa S, Satoh H, Horie R, Ito K, Choi SH, Takeuchi H, Watanabe T (1996) Cloning and characterization of a cDNA for rat CD30 homolog and chromosomal assignment of the genomic gene. Gene 182:155-162
28. 28. Fonatsch C, Latza U, Dürkop H, Rieder H, Stein H (1992) Assignment of the human CD30 (Ki-1)gene to 1p36. Genomics 14:825-826
29. 29. Kemper O, Derre J, Cherif D, Engelman H, Wallach D, Bergre R (1991) The gene for the type II (p75) tumor necrosis receptor (TNF-RII) is located on band 1p36.2-p36.3. Hum Genet 87:623-624
30. 30. Latza U, Dürkop H, Schmittger S, Ringaling J, Eitelbach F, Hummel M, Fonatsch C, Stein H (1994) The human OX40 homolog: cDNA structure, expression and chromosomal assignment of the ACT53 antigen. Eur J Immunol 24:677-683
31. 31. Younes A, Consoli U, Zhao S, Snell V, Thomas E, Gruss HJ, Cabanillas F, Andreeff M (1996) CD30 ligand is expressed on resting normal and malignant B lymphocytes. Br J Haematol 93:569-571
32. 32. Pinto A, Aldinucci D, Gloghini A, Zagonel V, Degan M, Importa S, Juzbasic S, Todesco M, Perin V, Gattei V, Hermann F, Grüss HJ, Carbone A (1996) Human eosinophils express functional CD30 ligand and stimulate proliferation of a Hodgkin's disease cell line. Blood 88:3299-3305
33. 33. Grüss HJ, Pinto A, Gloghini A, Wehnes E, Wright B, Boiani N, Aldinucci D, Gattei V, Zagonel V, Smith CA, Kadin ME, von Schilling C, Goodwin RG, Hermann F, Carbone A (1996) CD30 ligand expression in nonmalignant and Hodgkin's disease-involved lymphoid tissues. Am J Pathol 149:469-481
34. 34. Gattei V, Degan M, Gloghini A, De Iuliis A, Improta S, Rossi FM, Aldinucci D, Perin V, Serraino D, Babare R, Zagonel V, Grüss HJ, Carbone A, Pinto A (1997) CD30 ligand is frequently expressed in human hematopoietic malignancies of myeloid and lymphoid origin. Blood 89:2048-2059
35. 35. Romagnani P, Annunziato F, Manetti R, Mavilia C, Lasagni L, Manuelli C, Vannelli GB, Vanini V, Maggi E, Romagnani S (1998) High CD30 ligand expression by epithelial cells and Hassal's corpuscles in the medulla of human thymus. Blood 91:3323-3332
36. 36. Wiley SR, Goodwin RG, Smith CA (1996) Reverse signaling via CD30 ligand. J Immunol 157:3635-3639.
37. 37. Stuber E, Neurath M, Calderhead D, Fell HP, Strober W (1995) Crosslinking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells. Immunity 2:507-521
38. 38. van Essen D, Kikutani H, Gray D (1995) CD40 ligand-transduced costimulation of T cells in the development of helper function. Nature 378:620-623
39. 39. Schwarting R, Stein H (1989) Cluster report: CD30, in Leukocyte typing IV (Knapp W, Dorken B, Gilks WR, Rieber EP, Schmidt RE, Stein H, von dem Borne AEG, eds) p. 419. Oxford University, Oxford, UK, February 21-25
40. 40. Pallesen G (1990) The diagnostic significance of the CD30(Ki-1) antigen. Histopathology 16:409-413
41. 41. Hansen H, Bredfeldt G, Havsteen B, Lemke H (1990) Protein kinase activity of the intra cellular but not of the membrane-associated form of the Ki-1 antigen (CD30). Res Immunol 141:13-31
42. 42. Rohde D, Hansen H, Hafner M, Lange H, Mielke V, Hansmann ML, Lemke H (1992) Cellular localizations and processing of the two molecular forms of the Hodgkin-associated Ki-1 (CD30) antigen. The protein kinase Ki-1/57 occurs in the nucleus. Am J Pathol 140:473-482
43. 43. Kobarg J, Schnittger S, Fonatsch C, Lemke H, Bowen MA, Buck F, Hansen HP (1997) Characterization, mapping and partial cDNA sequence of the 57-kD intracellular Ki-1 antigen. Exp Clin Immunogen 14:273-280
44. 44. Falini B, Pileri S, Pizzolo G, Dürkop H, Flenghi L, Stirpe F, Martelli MF, Stein H (1995) CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 85:1-14
45. 45. Ito K, Watanabe T, Horie R, Shiota M, Kawamura S, Mori S (1994) High expression of the CD30 molecule in human decidual cells. Am J Pathol 145:276-280
46. 46. Shanebeck KD, Maliszewski CR, Kennedy MK, Picha KS, Smith CA, Goodwin RG, Grabstein KH (1995) Regulation of murine B cell growth and differentiation by CD30 ligand. Eur J Immunol 25:2147-2153
47. 47. Agrawal B, Reddish M, Longenecker M (1996) CD30 expression on human CD8 + T cells isolated from peripheral blood lymphocytes of normal donors. J Immunol 157:3229-3234
48. 48. Romagnani P, Annunziato F, Manetti R, Mavilia C, Lasagni L, Manuelli C, Vannelli GB, Vanini V, Maggi E, Romagnani S (1998) High CD30 ligand expression by epithelial cells and Hassal's corpuscles in the medulla of human thymus. Blood 91:3323-3332
49. 49. Gerdes J, Schwarting R, Stein H (1986) High proliferative activity of Reed Sternberg associated antigen Ki-1 positive cells in normal lymphoid tissue. J Clin Pathol 39:993-997
50. 50. Abbondanzo SL, Sato N, Straus SE, Jaffe ES (1990) Acute infectious mononucleosis. CD30 (Ki-1) antigen expression and histologic correlations. Am J Clin Pathol 93:698-702
51. 51. Ralfkiaer E, Bosq J, Gatter KC, Schwarting R, Gerdes J, Stein H, Mason DY (1987) Expression of a Hodgkin and Reed-Sternberg cell associated antigen (Ki-1) in cutaneous lymphoid infiltrates. Arch Dermatol Res 279:285-292
52. 52. Romagnani S, Prete GD, Maggi E, Chilosi M, Caligaris-Cappio F, Pizzolo G (1995) CD30 and type 2 T helper (Th2) responses. J Leukocyte Biol 57:726-730
53. 53. Del Prete G, De Carli M, Almerigogna F, Danniel CK, D'Elois MM, Zancuoghi G, Vinante G, Pizzolo G, Romagnani S (1995) Preferential expression of CD30 by human CD4 + T cells producing Th2-type cytokines. FASEB J 9:81-86
54. 54. Maggi E, Giudizi M-G, Biangiotti R, Annunziato F, Manetti R, Piccini MP, Parronchi P, Sampognaro S, Giannarini L, Zuccati G, Romagnani S (1994) Th2-like CD8 + T cells showing B cell helper function and reduced cytolytic activity in human immunodeficiency virus type 1 infection. J Exp Med 180:489-495
55. 55. Manetti R, Annunziato F, Biagiotti R, Giudizi MG, Piccini M-P, Giannarini L, Sampognaro S, Parronchi P, Vinante F, Pizzolo G, Maggi E, Romagnani S (1994) CD30 expression by CD8 T cells producing type 2 helper cytokines. Evidence for large numbers of CD8 + CD30 + T cell clones in human immunodeficiency virus infection. J Exp Med 180:2407-2411
56. 56. Del Prete G, Maggi E, Pizzolo G, Romagnani S (1995) CD30, Th2 cytokines and HIV infection: a complex and fascinating link. Immunol Today 16:76-80
57. 57. Hamann D, Hilkens CMU, Grogan JL, Lens SMA, Kapsenberg ML, Yazdanbakhsh M, van Lier RAW (1996) CD30 expression does not discriminate between Th1-and Th2-type T cells. J Immunol 156:1387-1391
58. 58. Alzona M, Jack H-M, Fisher RI, Ellis TM (1994) CD30 defines a subset of activated human T cells that produce IFN-γ and IL-5 and exhibit enhanced B cell helper activity. J Immunol 153:2861-2867
59. 59. Gilfillan MC, Noel PJ, Podack ER, Reiner SL, Thompson CB (1998) Expression of the costimulatory receptor CD30 is regulated by both CD28 and cytokines. J Immunol 160:2180-2187
60. 60. Nakamura T, Lee RK, Nam SY, Al-Ramadi BK, Koni PA, Bottomly K, Podack ER, Flavell RA (1997) Reciprocal regulation of CD30 expression on CD4 + T cells by IL-4 and IFN-γ. J Immunol 158:2090-2098
61. 61. Bluestone JA (1995) New perspectives of CD28-B7-mediated T cell costimulation. Immunity 2:555-559
62. 62. Brown DR, Green JM, Moskowitz NH, Davis M, Thompson CB, Reiner SL (1996) Limited role of CD28-mediated signals in T helper subset differentiation. J Exp Med 184:803-810
63. 63. Ohtsuka E, Kikuchi H, Nasu M, Takita-Sonoda Y, Fujii H, Yokoyama S (1994) Clinicopathological features of adult T-cell leukemia with CD30 antigen expression. Leukemia Lymphoma 15:303-310
64. 64. Takeshita M, Akamatsu M, Ohshima K, Kobari S, Kikuchi M, Suzumiya J, Uike N, Okamura T (1995) CD30 (Ki-1) expression in adult T-cell leukaemia/lymphoma is associated with distinct immunohistological and clinical characteristics. Histopathology 26:539-546
65. 65. Pallesen G, Hamilton-Dutoit SJK (1988) Ki-1 (CD30) antigen is regularly expressed by tumor cells of embryonal carcinoma. Am J Pathol 133:446-450
66. 66. Latza U, Foss HD, Dürkop H, Eitelbach E, Dieckmann KP, Loy V, Unger M, Pizzolo G, Stein H (1995) CD30 antigen in embryonal carcinoma and embryogenesis and release of the soluble form. Am J Pathol 146:463-471
67. 67. Mechtersheimer G, Moller P (1990) Expression of Ki-1 antigen (CD30) in mesenchymal tumours. Cancer 66:1732-1737
68. 68. Hansen HP, Kisselva T, Kobarg J, Horn-Lohrens O, Havsteen B, Lemke H (1995) A zinc metalloproteinase is responsible for the release of CD30 on human tumor cell lines. Int J Cancer 63:750-756
69. 69. Pfreundschuh M, Pohl C, Berenbeck C, Schroeder J, Jung W, Schmits R, Tschiersch A, Diehl V, Gause A (1990) Detection of a soluble form of the CD30 antigen in sera of patients with lymphoma, adult T-cell leukemia and infectious mononucleosis. Int J Cancer 45:869-874
70. 70. Fattovich G, Vinante F, Giustina G, Morosato L, Alberti A, Ruol A, Pizzolo G (1996) Serum levels of soluble CD30 in chronic hepatitis B virus infection. Clin Exp Immunol 103:105-110
71. 71. Pizzolo G, Vinante F, Morosato L, Nadali G, Chilosi M, Gandini G, Sinicco A, Raiteri R, Semenzato G, Stein H, Perona G (1994) High serum levels of the soluble form of CD30 molecule in the early phase of HIV-1 infection as an independent predictor for progression of AIDS. AIDS 8:741-745
72. 72. Pizzolo G, Vinante F, Nadali G, Krampera M, Morosato L, Chilosi M, Raiteri R, Sinicco A (1997) High serum level of soluble CD30 in acute primary HIV-1 infection. Clin Exp Immunol 108:251-253
73. 73. Gerli R, Muscat C, Bistoni O, Fakini B, Tomassini C, Agea E, Tognellini R, Biagini P, Bertotto A (1995) High levels of the soluble form of CD30 molecule in rheumatoid arthritis (RA) are expression of CD30 + T cell involvement in the inflamed joints. Clin Exp Immunol 102:547-550
74. 74. Giacomelli R. Cipriani P, Lattanzio R, Di Franco M, Locanto M, Parzanese I, Passacantando A, Ciocci A, Tonietti G (1997) Circulating levels of soluble CD30 are increased in patients with systemic sclerosis (SSc) and correlate with serological and clinical features of the disease. Clin Exp Immunol 108:42-46
75. 75. Bengtsson A, Holm L, Bäck O, Fransson J, Scheynius A (1997) Elevated serum levels of soluble CD30 in patients with atopic dermatitis (AD). Clin Exp Immunol 109:533-537
76. 76. Wang G, Hansen H, Tatsis E, Csernok E, Lemke H, Gross WL (1997) High plasma levels of the soluble form of CD30 activation molecule reflect disease activity in patients with Wegener's granulomatosis. Am J Med 102:517-523
77. 77. Okumura M, Hidaka Y, Kuroda S, Takeoka K, Tada H, Amino N (1997) Increased serum concentration of soluble CD30 in patients with Graves' disease and Hashimoto's thyroiditis. J Clin Endocrinol Metab 82:1757-1760
78. 78. Chilosi M, Facchetti F, Notarangelo LD, Romagnani S, Del Prete G, Almerigogna F, De Carli M, Pizzolo G (1995) CD30 cell expression and abnormal soluble CD30 serum accumulation in Omen's syndrome: evidence for a T helper 2-mediated condition. Eur J Immunol 26:329-334
79. 79. Dallenbach F, Josimovic-Alasevic O, Durkop H, Schwarting R, Diamantstein T, Matsuoka M, Takatsuki K, Stein H (1989) Soluble CD30 antigen in the sera of patients with adult T-cell lymphoma/leukemia (ATL): a marker for disease activity, in Leukocyte typing IV (Knapp W, Dorken B, Gilks WR, Rieber EP, Schmidt RE, Stein H, von dem Borne AEG eds) p. 426. Oxford University, Oxford, UK
80. 80. Gause A, Pohl C, Tschiersch A, Costa LD, Jung W, Diehl V, Hasenclever D, Pfreundschuh M (1991) Clinical significance of soluble CD30 antigen in the sera of patients with untreated Hodgkin's disease. Blood 77:1983-1988
81. 81. Nadali G, Vinante F, Ambrosetti A, Todeschini G, Veneri D, Zanotti R, Meneghini V, Ricetti MM, Benedetti F, Vassanelli A, Perona G, Chisoli M, Menestrina F, Fiacchini M, Stein H, Pizzolo G (1994) Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis. J Clin Oncol 12:793-797
82. 82. Nadali G, Tavecchia L, Zanolin E, Bonfante V, Viviani S, Camerini E, Musto P, Di Renzo N, Carotenuto M, Chilosi M, Krampera M, Pizzolo G (1998) Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome. Blood 91:3011-3016
83. 83. Zinzani PL, Pileri S, Bernardi M, Buzzi M, Sabatini E, Ascari S, Gherlinzoni F, Magagnoli M, Albertini P, Tura S (1998) Clinical implications of serum levels of soluble CD30 in 70 adult anaplastic large-cell lymphoma patients. J Clin Oncol 16:1532-1537
84. 84. Luigi P, Pileri S, Bendandi M, Buzzi M, Sabattini E, Ascani S, Gherlinzoni F, Magagnoli M, Albertini, Tura S (1998) Clinical implications of serum levels of soluble CD30 in 70 adult anaplastic large-cell lymphoma patients. J Clin Oncol 16:1532-1537
85. 85. Grüss HJ, Hermann F (1996) CD30 ligand, a member of the TNF ligand superfamily, with growth and activation control for CD30 + lymphoid and lymphoma cells. Leukemia lymphoma 20:397-409
86. 86. Maggi E, Annunziato F, Manetti R, Biagiotti R, Giudizi MG, Ravina A, Almerigogna F, Boiani N, Alderson M, Romagnani S (1995) Activation of HIV expression by CD30 triggering in CD4 + T cells from HIV-infected individuals. Immunity 3:251-255
87. 87. Lee SY, Park CG, Choi Y (1996) T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptor-associated factors. J Exp Med 183:669-674
88. 88. Telford WG, Nam SY, Podack ER, Miller RA (1997) CD30-regulated apoptosis in murine CD8 T cells after cessation of TCR signals. Cell Immunol 182:125-136
89. 89. Amakawa R, Hakem A, Kundig TM, Matsuyama T, Simard JJL, Timms E, Wakeham A, Mittruecker HW, Griesser H, Takimoto H, Schmits R, Shahinian A, Ohashi PS, Penninger JM, Mak TW (1996) Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice. Cell 84:551-562
90. 90. Jumper MD, Nishioka Y, Davis LS, Lipsky PE, Meek K (1995) Regulation of human B cell proliferation by recombinant CD40 ligand and other TNF-related ligands. J Immunol 155:2369-2378
91. 91. Horie R, Ito K, Tatewaki M, Nagai M, Aizawa S, Higashihara M, Ishida T, Inoue J, Takizawa H, Watanabe T (1996) A variant CD30 protein lacking extracellular and transmembrane domains is induced in HL-60 by tetradecanoylphorbol acetate and is expressed in alveolar macrophages. Blood 88:2422-2432
92. 92. Grüss HJ, Scheffrahn I, Hubinger G, Duyster J, Hermann F (1996) The CD30 ligand and CD40 ligand regulate CD54 surface expression and release of its soluble form by cultured Hodgkin and Reed-Sternberg cells. Leukemia 10:829-835
93. 93. Grüss HJ, Ulrich D, Dower SK, Herrmann F, Brach MA (1996) Activation of Hodgkin cells via the CD30 receptor induced autocrine secretion of interleukin-6 engaging the NF-κ B transcription factor. Blood 87:2443-2449
94. 94. Malinin NL, Boldin MP, Kovalenko AV, Wallach D (1997) MAP3K-related kinase involved in NF-κ B induction by TNF, CD95 and IL-1. Nature 385:540-544
95. 95. Hu HM, O'Rourke K, Boguski MS, Dixit VM (1994) A novel RING finger protein interacts with the cytoplasmic domain of CD40. J Biol Chem 269:30069-30072
96. 96. Rothe M, Wong SC, Henzel WJ, Goeddel DV (1994) A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell 78:681-692
97. 97. Cheng G, Cleary AM, Ye Z-S, Hong DI, Lederman S, Baltimore D (1995) Involvement of CRAF1, a relative of TRAF, in CD40 signaling. Science 267:1494-1498
98. 98. Mosialos G, Birkenbach M, Yalamachili R, VanArsdale T, Ware C, Kieff E (1995) The Epstein-Barr virus transforming protein LMP1 engages signal proteins for the tumor necrosis factor receptor family. Cell 80:389-399
99. 99. Regnier CH, Tomasetto C, Moog-Lutz C, Chenard MP, Wendung C, Basset P, Rio MC (1995) Presence of a new conserved domain in CART1, a novel member of the tumor necrosis factor receptor-associated protein family, which is expressed in breast carcinoma. J Biol Chem 270:25715-25721
100. 100. Sato T, Irie S, Reed JC (1995) A novel member of the TRAF family of putative signal transducing proteins binds to the cytoplasmic domain of CD40. FEBS Lett 358:113-118
101. 101. Song HY, Donner DB (1995) Association of a RING finger protein with the cytoplasmic domain of the human type-2 tumor necrosis factor. Biochem J 809:825-829
102. 102. Nakano H, Oshima H, Chung W, Williams-Abbott L, Ware CF, Yagita H, Okumura K (1996) TRAF5, an activator of NF-κ B and putative signal transducer for the lymphotoxin-beta receptor. J Biol Chem 271:14661-14664
103. 103. Ishida T, Tojo T, Aoki T, Kobayashi N, Ohishi T, Watanabe T, Yamamoto T, Inoue J (1996) TRAF-5, a novel TRAF family protein, mediates CD40 signaling. Proc Natl Acad Sci 93:9437-9442
104. 104. Cao Z, Xiong J, Takeuchi M, Kurama T, Goeddel DV (1996) TRAF6 is a signal transducer for interleukin 1. Nature 383:443-446
105. 105. Ishida T, Mizushima S, Kobayashi N, Tojo T, Aizawa S, Watanabe T, Mosialos G, Kieff E, Yamamoto T, Inoue J (1996) Identification of TRAF6, a novel TRAF protein that mediates signaling from an amino-terminal domain of the CD40 cytoplasmic region. J Biol Chem 271:28745-28748
106. 106. Horie R, Aizawa S, Nagai M, Ito K, Higashihara M, Ishida T, Inoue J, Watanabe T (1998) A novel domain in the CD30 cytoplasmic tail mediates NF-κ B activation. Int Immunol 10:203-210
107. 107. Duckett CS, Thompson CB (1997) CD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival. Gene Dev 11:2810-2821
108. 108. Hsu H, Solovyev I, Colomero A, Elliot R, Kelly M, Boyle WJ (1997) ATAR, a novel tumor necrosis factor receptor family member, signals through TRAF2 and TRAF5. J Biol Chem 272:13471-13474
109. 109. Marsters SA, Ayres TM, Skubatch M, Gray CL, Rothe M, Ashkenazi A (1997) Herpes entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates the transcription factors NF-κ B and AP-1. J Biol Chem 272:14029-14032
110. 110. Kawamata S, Hori T, Imura A, Takaori-Kondo A, Uchiyama T (1998) Activation of OX40 signal transduction pathways leads to tumor necrosis factor receptor-associated factor (TRAF) 2-and TRAF5-mediated NF-κ B activation. J Biol Chem 273:5808-5814
111. 111. Akiba H, Nakano H, Nishinaka S, Shindo M, Kobata T, Atsuta M, Morimoto C, Ware CF, Malinin NL, Wallach D, Yagita H, Okumura K (1998) CD27, a member of the tumor necrosis factor receptor superfamily, activates NF-κ B and stress-activated protein kinase/c-Jun N-terminal kinase via TRAF2, TRAF5, and NF-κ B-inducing kinase. J Biol Chem 273:13353-13358
112. 112. Mercuric F, Zhu H, Murray BW, Shevchenko A, Bennett BL, Li JW, Young DB, Barbosa M, Mann M, Manning A, Rao A (1997) IKK1 and IKK2: Cytokine-activated IkB kinases essential for NF-κ B activation. Science 278:860-866
113. 113. Woronicz JD, Gao X, Cao Z, Rothe M, Goeddel DV (1997) IkB kinase-β: NF-κ B activation and complex formation with IkB kinase-α and NIK. Science 278:866-869
114. 114. Nakano H, Shindo M, Sakon S, Nishikawa S, Mihara M, Yagita H, Okumura K (1998) Differential regulation of IkB kinase a and b by two upstream kinases, NF-κ B-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1. Proc Natl Acad Sci 95:3537-3542
115. 115. Lee FS, Hagler J, Chen ZJ, Maniatis T (1997) Activation the IkB kinase complex by MEKK1, a kinase of the JNK pathway. Cell 88:213-222
116. 116. Song HY, Regnier C, Kirschning CJ, Goeddel DV, Rothe M (1997) Tumor necrosis factor (TNF)-mediated kinase cascades: bifurcation of nuclear factor-kB and c-jun N-terminal kinase (JNK/SAPK) pathways at TNF receptor-associated factor 2. Proc Natl Acad Sci 94:9792-9796
117. 117. Natoli G, Costanzo A, Moretti F, Fulco M, Balsano C, Levrero M (1997) Tumor necrosis factor (TNF) receptor signaling downstream of TNF receptor-associated factor 2: nuclear factor kB (NFκ B)-inducing kinase requirement for activation of activating protein 1 and NFκ B but not of c-jun N-terminal kinase/stress-activated protein kinase. J Biol Chem 272:26079-26082
118. 118. Lee SY, Reichlin A, Santana A, Sokol KA, Nussenzweig MC, Choi Y (1997) TRAF2 is essential for JNK but not NF-κ B activation and regulates lymphocyte proliferation and survival. Immunity 7:703-713
119. 119. Hsu H, Shu HB, Pan MG, Goeddel DV (1996) TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 84:299-308
120. 120. Liu Z-G, Hsu H, Goeddel DV, Karin M (1996) Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-κ B activation prevents cell death. Cell 87:565-576
121. 121. Natoli G, Costanzo A, Ianni A, Templeton DJ, Woodgett JR, Balsano C, Levrero M (1997) Activation of SAPK/JNK by TNF receptor 1 through a noncytotoxic TRAF2-dependent pathway. Science 275:200-203
122. 122. Reinhard C, Shamoon B, Shyamala V, Williams LT (1997) Tumor necrosis factor α-induced activation of c-jun N-terminal kinase is mediated by TRAF2. EMBO J 16:1080-1092
123. 123. Engert A, Martin G, Pfreundschuh M, Andot P, Hsu SM, Diehl V, Thorpe P (1990) Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumours in mice. Cancer Res 50:2929-2935
124. 124. Tazzari PL, Bolognesi A, De Totero D, Falini B, Lemoli RM, Soria MR, Pileri S, Gobbi M, Stein H, Flenghi L, Martelli MF, Stirpe F (1992) Ber-H2 (anti CD30)-saporin immunotoxin: A new tool for the treatment of Hodgkin's disease and CD30 + lymphoma. in vitro evaluation. Br J Haematol 81:203-211